Pharmaceutical firm Elan has sold its interests in anti-epileptic drug Zonegran to Eisai for $130m (€106.41m) if the deal is finalised by the end of April.

ROLL up, roll up, the great Elan sell-off continues and the more the company sells off the higher its share price goes.

ELAN’s ongoing problems with the US Securities and Exchange Commission over its accounting procedures is the main inhibitor to investors after the company posted stronger than expected sales’ growth yesterday.